BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30799646)

  • 1. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
    Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
    Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of molecular alterations with immune response in melanoma.
    Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
    Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.
    Sorich MJ; Rowland A; Hopkins AM
    Melanoma Res; 2020 Jun; 30(3):268-271. PubMed ID: 31425480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
    Luke JJ; Hodi FS
    Oncologist; 2013 Jun; 18(6):717-25. PubMed ID: 23709751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
    Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
    Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
    Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Kozłowska-Wojciechowska M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):329-334. PubMed ID: 30386910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.
    Ghate SR; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Curr Med Res Opin; 2018 Dec; 34(12):2169-2176. PubMed ID: 30009647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.